Paradromics

Matt Angle shared that Connexus is pulling down info transfer rates north of 100bps in pre-clinical testing! We are very excited to study the restoration of communication at natural speeds, made possible by our BCI platform, capable of recording at rates 10Xs what is currently available in other, early BCI trials. We are bringing world-class physicans (David Brandman, MD, PhD and Daniel Rubin, MD, PhD) and advanced neurotech befitting of their skills together in the Connexus BCI clinical trial. Special thanks to Walt Maciborski for the feature: https://lnkd.in/gawwKwPJ UC Davis Health, UC Davis Department of Neurological Surgery, Massachusetts General Hospital

We are excited to announce David Brandman, MD, PhD, neurosurgeon in the Department of Neurological Surgery at University of California, Davis as study principal investigator and Daniel Rubin, M.D., Ph.D., critical care neurologist at Massachusetts General Hospital, as investigator for the upcoming Connexus BCI Clinical Study. We are looking forward to working with these exceptional leaders in clinical BCI technology. “I am excited to lead the Connexus BCI Clinical Study… This research is an important step for the field of BCI technology, investigating how BCI users can communicate through synthesized speech and text.” - Dr. Brandman “For people unable to communicate due to motor impairment, there is significant unmet medical need…I look forward to the upcoming Connexus BCI Clinical Study and am excited to explore how rich, high bandwidth brain data can produce real-time, accurate communication.” - Dr. Rubin We are one step closer to the Connexus BCI Clinical Study launching later this year! Learn more: https://lnkd.in/gCR84TSA

“If we didn’t do it, it felt like no one would do it. We were in contact with a lot of the labs that were doing BCI research at the time and we knew that those paradigms were data limited. The only thing preventing patients from having more useful systems, doing more things, is they were essentially transmitting data through this tiny little soda straw and there was no engineering reason why it couldn’t be 10 or 100 times better.” - Matt Angle Above quote pulled from Vivek Garipalli's Wormhole Capital Podcast, which explores Paradromics and Matt’s origin stories. His interview should provide hope to aspiring entrepreneurs, demonstrating that success can spring from brilliance, drive, and lack-luster grades! A huge thanks to Vivek for this entertaining deepdive into the history and future of both BCIs and Paradromics - watch here: https://lnkd.in/gxSXGrw4

We are excited to welcome Reema Khan to the Paradromics Team! Reema will be joining us as Chief Strategy Officer. Her talent for identifying and steering transformative technology into growth will be critical for Paradromics as we approach our first-in-human surgeries later this year. Reema founded Green Sands Equity in 2016, where she is responsible for investment strategy, team, and operations across their global network. Green Sands Equity focuses on investments in Space, Technology, Healthcare, and Frontier Tech, with investments in iconic companies like Spotify, SpaceX, Airbnb, Pasqal, and Colossal.

There are incredible things happening in the neurotechnology?field.?Emily Mullin at?WIRED?highlighted another exciting startup in the space. Matt Angle commented that the technology is a pragmatic way to digitize smell because “it leverages the very hard-to-engineer physiology of olfaction while still getting the benefit of digitization and rapid analysis.” https://lnkd.in/gS4RbcPJ

Ashley Capoot at CNBC covered our recent announcement of a strategic investment from NEOM Investment Fund (NIF). “Working together, we can accelerate the rate of innovation in BCI and expand access to impactful BCI-based therapies.” - Paradromics CEO Matt Angle https://lnkd.in/d3RUEpGM

We are thrilled to announce an investment by NEOM Investment Fund (NIF) in Paradromics. Paradromics and NEOM are aligned on an expansive vision of a future with impactful BCI-based therapies. Through this strategic partnership, Paradromics can accelerate our BCI innovations. https://lnkd.in/gzzusi2q

Today Matt Angle explored how BCIs will tackle unsolved brain-health problems from the Tech Arena at #LEAP25! What an exciting time to be at Paradromics and in the field of #BCI.

Paradromics is headed to #LEAP25! Matt Angle will be discussing the future of neurotech–from mental health monitoring to cognitive interfaces–live at the Tech Arena with MAHMOUD ALYAMANY MD, Health and Well-Being Sector Head at NEOM. Learn more: https://lnkd.in/g6zEHTSB

We are excited to be joining BrainMind during J.P. Morgan Week! Paradromic’s CEO Matt Angle will be presenting a Lightning Pitch today alongside other incredible innovators in the neurotech space. ?? Paradromics’ #BCI records brain activity at the highest possible resolution: the individual neuron. We translate each unique signal in real time, enabling the seamless translation of thought into action. https://lnkd.in/gRRKNm2X